The Arden House Conference on Tuberculosis, Revisited: Perspectives for Tuberculosis Elimination in the United States

In 1959, the Arden House Conference on Tuberculosis inaugurated modern tuberculosis control strategy by declaring that curative treatment of tuberculosis is a public health obligation. In the decades after the conference, tuberculosis rates decreased more slowly than forecast, perhaps because chemotherapy had less impact than anticipated, or because the conference's recommendations were not implemented fully until 30 years later, when an epidemic resurgence jolted the country out of complacency. Since 1959, several broad issues have gained prominence after being overlooked or unexpected at the time of the Arden House Conference. These include tuberculosis outbreaks, contact investigations, treatment of latent Mycobacterium tuberculosis infection, briefer treatment regimens, human immunodeficiency virus infection, bacteriology laboratory capabilities, and transnational migration. Trends and experience have shown that tuberculosis elimination in the United States will be unfeasible until both technological advances and social justice allow control systems to be applied throughout the world.

Tuberculosis epidemiology - tuberculosis treatment - tuberculosis prevention - tuberculosis funding - medical history

REFERENCES

• 1 The Arden House Conference on Tuberculosis .U.S. Department of Health, Education, and Welfare, Public Health Service Publication No. 784. Washington, DC; U.S. Government Printing Office 1961
• 2 Ferebee S H, Mount F W, Palmer C E. Tuberculosis prophylaxis trials in preview.  Public Health Rep. 1957;  72 703-704
• 3 Davey W N. Arden House: the unfinished edifice.  American Lung Association Bulletin. 1982;  March 18-20
• 4 Institute of Medicine Committee on the Elimination of Tuberculosis in the United States .Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC; Institute of Medicine 2000
• 5 Carson R. Silent Spring. New York; Houghton Mifflin 1962
• 6 CDC . Essential components of a tuberculosis prevention and control program (ACET).  MMWR Morb Mortal Wkly Rep. 1995;  44(RR-11) 1-16
• 7 Reported tuberculosis data, 1960 edition .U.S. Department of Health, Education, and Welfare, Public Health Service Publication No. 638. Washington, DC; U.S. Government Printing Office 1960
• 8 Reported tuberculosis data, 1965 edition .U.S. Department of Health, Education, and Welfare, Public Health Service Publication No. 638. Washington, DC; U.S. Government Printing Office 1965
• 9 Frost W H. The age selection of mortality from tuberculosis in successive decades.  Am J Hyg. 1939;  30 91-96
• 10 Comstock G W. Re: The age of selection of mortality from tuberculosis in successive decades.  Am J Epidemiol. 1995;  141 790
• 11 Styblo K. Epidemiology of tuberculosis. Reissued: revised and expanded. Selected Papers, Vol 24 The Hague; Royal Netherlands Tuberculosis Association 1991: 9-115
• 12 Vynnycky E, Fine P E. Lifetime risks, incubation period, and serial interval of tuberculosis.  Am J Epidemiol. 2000;  152 247-263
• 13 Brudney K, Dokbin J. Resurgent tuberculosis in New York City.  Am Rev Respir Dis. 1991;  144 745-749
• 14 Cantwell M F, Snider D E, Cauthen G M, Onorato I M. Epidemiology of tuberculosis in the United States, 1985 through 1992.  JAMA. 1994;  272 535-539
• 15 Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City-turning the tide.  N Engl J Med. 1995;  333 229-233
• 16 Barr R G, Diez-Roux A V, Knirsch C A, Pablos-Méndez A. Neighborhood poverty and the resurgence of tuberculosis in New York City, 1984-1992.  Am J Public Health. 2001;  91 1487-1493
• 17 Rieder H L, Cauthen G M, Comstock G W, Snider D E. Epidemiology of tuberculosis in the United States.  Epidemiol Rev. 1989;  11 79-98
• 18 Daniel T M, Debanne S M. Estimation of the annual risk of tuberculosis infection for white men in the United States.  J Infect Dis. 1997;  175 1535-1537
• 19 Trump D H, Hyams K C, Cross E R, Struewing J P. Tuberculosis infection among young adults entering the US Navy in 1990.  Arch Intern Med. 1993;  153 211-216
• 20 Cauthen G M, Pio A, ten Dam H G. Annual risk of tuberculous infection. 1988.  Bull World Health Organ. 2002;  80 503-511
• 21 Borgdorff M W. Annual risk of tuberculous infection: time for an update?.  Bull World Health Organ. 2002;  80 501-502
• 22 Barnes P F, Yang Z, Pogoda J M et al.. Foci of tuberculosis transmission in central Los Angeles.  Am J Respir Crit Care Med. 1999;  159 1081-1086
• 23 McNabb S J, Braden C R, Navin T R. DNA fingerprinting of Mycobacterium tuberculosis: lessons learned and implications for the future.  Emerg Infect Dis. 2002;  8 1314-1319
• 24 Van Helden P D. Molecular epidemiology of TB: challenging dogmas and asking new questions.  IUBMB Life. 2002;  53 219-223
• 25 Barnes P F, Yang Z, Preston-Martin S et al.. Patterns of tuberculosis transmission in Central Los Angeles.  JAMA. 1997;  278 1159-1163
• 26 Nguyen D, Proulx J F, Westley J, Thibert L, Dry S, Behr M A. Tuberculosis in the Inuit community of Quebec, Canada.  Am J Respir Crit Care Med. 2003;  168 1353-1357
• 27 Jasmer R M, Ponce de Leon A, Hopewell P C et al.. Tuberculosis in Mexican-born persons in San Francisco: reactivation, acquired infection and transmission.  Int J Tuberc Lung Dis. 1997;  1 536-541
• 28 Weis S E, Pogoda J M, Yang Z et al.. Transmission dynamics of tuberculosis in Tarrant county, Texas.  Am J Respir Crit Care Med. 2002;  166 36-42
• 29 Behr M A, Hopewell P C, Paz E A, Kawamura L M, Schecter G F, Small P M. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis .  Am J Respir Crit Care Med. 1998;  158 465-469
• 30 Bishai W R, Graham N M, Harrington S et al.. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy.  JAMA. 1998;  280 1679-1684
• 31 Small P M, Hopewell P C, Singh S P et al.. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods.  N Engl J Med. 1994;  330 1703-1709
• 32 Alland D, Kalkut G E, Moss A R et al.. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods.  N Engl J Med. 1994;  330 1710-1716
• 33 CDC . Progressing toward tuberculosis elimination in low-incidence areas of the United States: recommendations of the Advisory Council for the Elimination of Tuberculosis.  MMWR Morb Mortal Wkly Rep. 2002;  51(No. RR-5) 3-5
• 34 Cantwell M F, McKenna M T, McCray E, Onorato I M. Tuberculosis and race-ethnicity in the United States: impact of socioeconomic status.  Am J Respir Crit Care Med. 1997;  157 1016-1020
• 35 Bloom B R, Small P M. The evolving relation between humans and Mycobacterium tuberculosis .  N Engl J Med. 1998;  338 677-678
• 36 van Helden P D. The economic divide and tuberculosis: tuberculosis is not just a medical problem, but also a problem of social inequality and poverty.  EMBO Rep. 2003;  4 S24-S28
• 37 Collins J J. The contribution of medical measures to the decline of mortality from respiratory tuberculosis: an age-period-cohort model.  Demography. 1982;  19 409-427
• 38 Miller F JW, Thompson M D. Decline and fall of the tubercle bacillus: the Newcastle story 1882-1988.  Arch Dis Child. 1992;  67 251-255
• 39 Davies R PO, Tocque K, Bellis M A, Rimmington T, Davies P DO. Historical declines in tuberculosis in England and Wales: improving social conditions or natural selection?.  Int J Tuberc Lung Dis. 1999;  3 1051-1054
• 40 Borgdorff M W, Nagelkerke N J. Tuberculosis and natural selection.  Int J Tuberc Lung Dis. 2000;  4 885-889
• 41 Krieger N, Waterman P D, Chen J T, Soobader M J, Subramanian S V. Monitoring socioeconomic inequalities in sexually transmitted infections, tuberculosis, and violence: geocoding and choice of area-based socioeconomic measures-the public health disparities geocoding project (US).  Public Health Rep. 2003;  118 240-260
• 42 CDC . A strategic plan for the elimination of tuberculosis in the United States (ACET).  MMWR Morb Mortal Wkly Rep. 1989;  38(S-3) 1-25
• 43 CDC . Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment (ACET).  MMWR Morb Mortal Wkly Rep. 1999;  48(RR-9) 1-14
• 44 Dahle U R, Sandven P, Heldal E, Caugant D A. Continued low rates of transmission of Mycobacterium tuberculosis in Norway.  J Clin Microbiol. 2003;  41 2968-2973
• 45 Heldal E, Dahle U R, Sandven P et al.. Risk factors for recent transmission of Mycobacterium tuberculosis .  Eur Respir J. 2003;  22 637-642
• 46 Blower S M, McLean A R, Poroco T C et al.. The intrinsic transmission dynamics of tuberculosis epidemics.  Nat Med. 1995;  1 815-821
• 47 Vynnycky E, Fine P E. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection.  Epidemiol Infect. 1997;  119 183-201
• 48 Lillebaek T, Dirksen A, Vynnycky E, Baess I, Thomsen V O, Andersen A B. Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection.  J Infect Dis. 2003;  188 1032-1039
• 49 Riley E A. Tuberculous meningitis in the adult: a review of sixty consecutive streptomycin-treated cases.  Trans Annu Meet Natl Tuberc Assoc. 1952;  48 223-230
• 50 Murphy J D, Becker B B. An intermediary report on 102 streptomycin-protected pulmonary resections.  Trans Annu Meet Natl Tuberc Assoc. 1952;  48 231-237
• 51 Selikoff I J, Robitzek E H, Ornstein G G. Treatment of pulmonary tuberculosis with hydrazid derivatives of isonicotinic acid.  JAMA. 1952;  150 973-980
• 52 Clark C M, Elmendorf D F, Cawthon C U, Muschenheim C, McDermott W. Isoniazid (isonicotinic acid hydrazide) in the treatment of miliary and meningeal tuberculosis.  Am Rev Tuberc. 1952;  66 391-415
• 53 McDermott W. Isonicotinic acid derivatives in tuberculosis treatment: history of the development of the drugs.  Trans Annu Meet Natl Tuberc Assoc. 1952;  48 421-424
• 54 El-Sadr W M, Perlman D C, Denning E, Matts J P, Cohn D L. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.  Clin Infect Dis. 2001;  32 623-632
• 55 Nunn P P, Elliott A M, McAdam K P. Tropical respiratory medicine, II: Impact of human immunodeficiency virus on tuberculosis in developing countries.  Thorax. 1994;  49 511-518
• 56 Eltringham I J, Drobniewski F. Multiple drug resistant tuberculosis: aetiology, diagnosis and outcome.  Br Med Bull. 1998;  54 569-578
• 57 Willcox P A. Drug-resistant tuberculosis.  Curr Opin Pulm Med. 2000;  6 198-202
• 58 Comstock G W, Philip R N. Decline of the tuberculosis epidemic in Alaska.  Public Health Rep. 1961;  76 19-24
• 59 Comstock G W, Baum C, Snider Jr D E. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies.  Am Rev Respir Dis. 1979;  119 827-830
• 60 Flanders N E. Tuberculosis in western Alaska 1900-1950.  Polar Rec (Gr Brit). 1987;  23 383-396
• 61 Grzybowski S, Dorken E. Tuberculosis in Inuit.  Ecol Dis. 1983;  2 145-148
• 62 Comstock G W, Porter M E. Tuberculin sensitivity and tuberculosis among natives of the lower Yukon.  Public Health Rep. 1959;  74 621-634
• 63 Enarson D A, Grzybowski S. Incidence of active tuberculosis in the native population of Canada.  CMAJ. 1986;  134 1149-1152
• 64 Beller M, Middaugh J P. Surveillance for tuberculosis in Alaska, 1986.  Alaska Med. 1989;  31 4-8
• 65 McKenna M T, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993.  N Engl J Med. 1995;  332 1071-1076
• 66 Zuber P L, McKenna M T, Binkin N J, Onorato I M, Castro K G. Long-term risk of tuberculosis among foreign-born persons in the United States.  JAMA. 1997;  278 304-307
• 67 Schneider E, Castro K G. Tuberculosis trends in the United States, 1992-2001.  Tuberculosis (Edinb). 2003;  83 21-29
• 68 Iademarco M F, Castro K G. Epidemiology of tuberculosis.  Semin Respir Infect. 2003;  18 225-240
• 69 Frieden T R, Sterling T R, Munsiff S S, Watt C J, Dye C. Tuberculosis.  Lancet. 2003;  362 887-899
• 70 DeCock K M, Chaisson R E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.  Int J Tuberc Lung Dis. 1999;  3 457-465
• 71 Puffer R R. Familial Susceptibility to Tuberculosis: Its Importance as a Public Health Problem. Cambridge; Harvard University Press 1946
• 72 Comstock G W. Tuberculosis in twins: a re-analysis of the Prophit survey.  Am Rev Respir Dis. 1978;  117 621-624
• 73 Muller-Hill B. The blood from Auschwitz and the silence of the scholars.  Hist Philos Life Sci. 1999;  21 331-365
• 74 Stead W W, Senner J W, Reddick W T, Lofgren J P. Racial differences in susceptibility to infection by Mycobacterium tuberculosis .  N Engl J Med. 1990;  322 422-427
• 75 Stead W W. Genetics and resistance to tuberculosis: could resistance be enhanced by genetic engineering?.  Ann Intern Med. 1992;  116 937-941
• 76 Bates J H, Stead W W. The history of tuberculosis as a global epidemic.  Med Clin North Am. 1993;  77 1205-1217
• 77 van Crevel R, Ottenhoff T H, van der Meer J W. Innate immunity to Mycobacterium tuberculosis .  Adv Exp Med Biol. 2003;  531 241-247
• 78 Daniel T M. The origins and precolonial epidemiology of tuberculosis in the Americas: can we figure them out?.  Int J Tuberc Lung Dis. 2000;  4 395-400
• 79 Gomez i Prat J, de Souza S M. Prehistoric tuberculosis in america: adding comments to a literature review.  Mem Inst Oswaldo Cruz. 2003;  98 S151-S159
• 80 Rieder H L. Tuberculosis among American Indians of the contiguous United States.  Public Health Rep. 1989;  104 653-657
• 81 Soule B, Soule J. Death at the Hiawatha asylum for insane Indians.  S D J Med. 2003;  56 15-18
• 82 Jones D S. The health care experiments at Many Farms: the Navajo, tuberculosis, and the limits of modern medicine, 1952-1962.  Bull Hist Med. 2002;  76 749-790
• 83 Ryan W. Blaming the Victim. New York; Pantheon 1971
• 84 Anon. Isoniazid in the treatment of pulmonary tuberculosis: a summary of the second report of the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council.  S Afr Med J. 1953;  27 461-462
• 85 Chum H J, O'Brien R J, Chonde T M, Graf P, Rieder H L. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993.  AIDS. 1996;  10 299-309
• 86 CDC . Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis.  MMWR Morb Mortal Wkly Rep. 1993;  42(RR-7) 1-8
• 87 Mahmoudi A, Iseman M D. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance.  JAMA. 1993;  270 65-68
• 88 Weis S E, Slocum P C, Blais F X et al.. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.  N Engl J Med. 1994;  330 1179-1184
• 89 Wilson R W, Yang Z, Kelley M et al.. Evidence from molecular fingerprinting of limited spread of drug-resistant tuberculosis in Texas.  J Clin Microbiol. 1999;  37 3255-3259
• 90 Agerton T B, Valway S E, Blinkhorn R J et al.. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States.  Clin Infect Dis. 1999;  29 85-92
• 91 Kempainen R, Nelson K, Williams D N, Hedemark L. Mycobacterium tuberculosis disease in Somali immigrants in Minnesota.  Chest. 2001;  119 176-180
• 92 Callister M E, Barringer J, Thanabalasingam S T, Gair R, Davidson R N. Pulmonary tuberculosis among political asylum seekers screened at Heathrow Airport, London, 1995-9.  Thorax. 2002;  57 152-156
• 93 Quitugua T N, Seaworth B J, Weis S E et al.. Transmission of drug-resistant tuberculosis in Texas and Mexico.  J Clin Microbiol. 2002;  40 2716-2724
• 94 Marras T K, Wilson J, Wang E E, Avendano M, Yang J W. Tuberculosis among Tibetan refugee claimants in Toronto: 1998 to 2000.  Chest. 2003;  124 915-921
• 95 Allos B M, Gensheimer K F, Bloch A B et al.. Management of an outbreak of tuberculosis in a small community.  Ann Intern Med. 1996;  125 114-117
• 96 Curtis A B, Ridzon R, Vogel R et al.. Extensive transmission of Mycobacterium tuberculosis from a child.  N Engl J Med. 1999;  341 1491-1495
• 97 Fitzpatrick L, Hardacker J, Heirendt W et al.. A preventable TB outbreak investigated through an intricate social network.  Clin Infect Dis. 2001;  33 1801-1806
• 98 CDC . Cluster of tuberculosis cases among exotic dancers and their close contacts: Kansas, 1994-2000.  MMWR Morb Mortal Wkly Rep. 2001;  50 291-293
• 99 Comstock G W, Woolpert S F, Livesay V T. Tuberculosis studies in Muscogee County, Georgia: twenty-year evaluation of a community trial of BCG vaccination.  Public Health Rep. 1976;  91 276-280
• 100 Comstock G W. Field trials of tuberculosis vaccines: how could we have done them better?.  Control Clin Trials. 1994;  15 247-276
• 101 Fine P EM, Carneiro I AM, Milstien J B, Clements C J. Issues Relating to the Use of BCG in Immunization Programmes. Geneva; World Health Organization 1999 WHO/V&B/99.23
• 102 Zhang L X, Tu D H, He G X et al.. Risk of tuberculosis infection and tuberculous meningitis after discontintuation of bacillus Calmette-Guérin in Beijing.  Am Rev Crit Care Med. 2000;  162 1314-1317
• 103 Colditz G A, Brewer T F, Berkey C S et al.. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature.  JAMA. 1994;  271 698-702
• 104 Colditz G A, Berkey C S, Mosteller F et al.. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.  Pediatrics. 1995;  96 29-35
• 105 Brewer T F. Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature.  Clin Infect Dis. 2000;  31 S64-S67
• 106 Fine P E. BCG: the challenge continues.  Scand J Infect Dis. 2001;  33 243-245
• 107 Fine P E. Vaccines, genes and trials.  Novartis Found Symp. 1998;  217 57-69
• 108 Wilson M E, Fineberg H V, Colditz G A. Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine.  Clin Infect Dis. 1995;  20 982-991
• 109 Smith D, Wiegeshaus E, Balasubramanian V. An analysis of some hypotheses related to the Chingelput bacille Calmette-Guérin trial.  Clin Infect Dis. 2000;  31 S77-S80
• 110 Fox W. The chemotherapy of pulmonary tuberculosis: a review.  Chest. 1979;  76 785-796
• 111 Cohn D L, Catlin B J, Peterson K L, Judson F N, Sbarbaro J A. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen.  Ann Intern Med. 1990;  112 407-415
• 112 Moulding T. Supervision of tuberculosis outpatient chemotherapy.  J Med Assoc State Ala. 1972;  41 503-508
• 113 Stead W W, Jurgens G H. Productivity of prolonged follow-up after chemotherapy for tuberculosis.  Am Rev Respir Dis. 1973;  108 314-320
• 114 CDC . Current trends: recommendations for health department supervision of tuberculosis patients.  MMWR Morb Mortal Wkly Rep. 1974;  23 75-76
• 115 Kane A, Pollak S, Brigham H. Domiciliary treatment of pulmonary tuberculosis; the Seton Hospital home care program.  Dis Chest. 1953;  23 518-531
• 116 Moodie A S. Mass ambulatory chemotherapy in the treatment of tuberculosis in a predominantly urban community.  Am Rev Respir Dis. 1967;  95 384-397
• 117 Yeager H, Medinger A E. Tuberculosis long-term care beds: have we thrown out the baby with the bathwater?.  Chest. 1986;  90 752-754
• 118 Bailey W C, Sbarbaro J A. Controversies in pulmonary medicine: all patients should receive directly observed therapy in tuberculosis.  Am Rev Respir Dis. 1988;  138 1075-1076
• 119 Leff D R, Leff A R. Tuberculosis control policies in the major metropolitan health departments in the United States, VI: Standard of practice in 1996.  Am J Respir Crit Care Med. 1997;  156 1487-1494
• 120 CDC . Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America.  MMWR Morb Mortal Wkly Rep. 2003;  52(RR-11) 1-77
• 121 Burman W J, Cohn D L, Rietmeijer C A, Judson F N, Sbarbaro J A, Reves R R. Short-term incarceration for the management of noncompliance with tuberculosis treatment.  Chest. 1997;  112 57-62
• 122 Pablos-Méndez A, Knirsch C A, Barr R G, Lerner B H, Frieden T R. Nonadherence in tuberculosis treatment: predictors and consequences in New York City.  Am J Med. 1997;  102 164-170
• 123 Chaulk C P, Friedman M, Dunning R. Modeling the epidemiology and economics of directly observed therapy in Baltimore.  Int J Tuberc Lung Dis. 2000;  4 201-207
• 124 Chaulk C P, Kazandjian V A. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel.  JAMA. 1998;  279 943-948
• 125 Bayer R, Stayton C, Desvarieux M, Healton C, Landesman S, Tsai W Y. Directly observed therapy and treatment completion for tuberculosis in the United States: is universal supervised therapy necessary?.  Am J Public Health. 1998;  88 1052-1058
• 126 Zwarenstein M, Schoeman J H, Vundule C, Lombard C J, Tatley M. A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis.  Int J Tuberc Lung Dis. 2000;  4 550-554
• 127 CDC . Targeted tuberculin testing and treatment of latent tuberculosis infection.  MMWR Morb Mortal Wkly Rep. 2000;  49(RR-6)
• 128 Binkin N J, Vernon A A, Simone P M et al.. Tuberculosis prevention and control activities in the United States: an overview of the organization of tuberculosis services.  Int J Tuberc Lung Dis. 1999;  3 663-674
• 129 Broekmans J F, Migliori G B, Rieder H L et al.. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group.  Eur Respir J. 2002;  19 765-775
• 130 British Thoracic Society . Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society.  Thorax. 2000;  55 887-901
• 131 Long R Canadian Tuberculosis Standards. 5th ed. Toronto; University of Toronto Press 2000
• 132 Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis: a general review.  Bibl Tuberc. 1970;  26 28-106
• 133 Krebs A. The IUAT trial on isoniazid preventive treatment in persons with fibrotic lung lesions.  Bull Int Union Tuberc. 1976;  51 193-201
• 134 Comstock G W. A comparison of purified tuberculins in the south-eastern USA.  Bull World Health Organ. 1960;  23 683-688
• 135 Edwards L B, Comstock G W, Palmer C E. Contributions of northern populations to the understanding of tuberculin sensitivity.  Arch Environ Health. 1968;  17 507-516
• 136 Moulding T. Chemoprophylaxis of tuberculosis: when is the benefit worth the risk and cost?.  Ann Intern Med. 1971;  74 761-770
• 137 Anon. Treatment of pulmonary tuberculosis with isoniazid: an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.  BMJ. 1952;  2 735-746
• 138 Gellis S N, Murphy R V. Hepatitis following isoniazid.  Dis Chest. 1955;  28 462-464
• 139 Merritt A D, Fetter B F. Toxic hepatic necrosis (hepatitis) due to isoniazid: report of a case with cirrhosis and death due to hemorrhage from esophageal varices.  Ann Intern Med. 1959;  50 804-810
• 140 Garibaldi R A, Drusin R E, Ferebee S H, Gregg M B. Isoniazid-associated hepatitis: report of an outbreak.  Am Rev Respir Dis. 1972;  106 357-365
• 141 Kopanoff D E, Snider D E, Caras G J. Isoniazid-related hepatitis.  Am Rev Respir Dis. 1978;  117 991-1001
• 142 Etkind S C, Veen J. Contact follow-up in high- and low-prevalence countries. In: Reichman LB, Hershfield ES TB: A Comprehensive International Approach. New York; Marcel Dekker 2000: 275-289
• 143 Reichler M R, Etkind S, Taylor Z, Castro K G. Tuberculosis contact investigations.  Int J Tuberc Lung Dis. 2003;  7 S325-S327
• 144 Jereb J, Etkind S C, Joglar O T, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999.  Int J Tuberc Lung Dis. 2003;  7 S384-S390
• 145 Sterling T R, Thompson D, Stanley R L et al.. A multi-state outbreak of tuberculosis among members of a highly mobile social network: implications for tuberculosis elimination.  Int J Tuberc Lung Dis. 2000;  4 1066-1073
• 146 Golub J E, Cronin W A, Obasanjo O O et al.. Transmission of Mycobacterium tuberculosis through casual contact with an infectious case.  Arch Intern Med. 2001;  161 2254-2258
• 147 Bock N N, Mallory J P, Mobley N, DeVoe B, Taylor B B. Outbreak of tuberculosis associated with a floating card game in the rural south: lessons for tuberculosis contact investigations.  Clin Infect Dis. 1998;  27 1221-1226
• 148 Raffalli J, Sepkowitz K A, Armstrong D. Community-based outbreaks of tuberculosis.  Arch Intern Med. 1996;  156 1053-1060
• 149 McElroy P D, Rothenberg R B, Varghese R et al.. A network-informed approach to investigating a tuberculosis outbreak: implications for enhancing contact investigations.  Int J Tuberc Lung Dis. 2003;  7 S486-S493
• 150 Sprinson J E, Flood J, Fan C S et al.. Evaluation of tuberculosis contact investigations in California.  Int J Tuberc Lung Dis. 2003;  7 S363-S368
• 151 Wilce M, Shrestha-Kuwahara R, Taylor Z, Qualls N, Marks S. Tuberculosis contact investigation policies, practices, and challenges in 11 U.S. communities.  J Public Health Manag Pract. 2002;  8 69-78
• 152 Cooksey R C. Recent advances in laboratory procedures for pathogenic mycobacteria.  Clin Lab Med. 2003;  23 801-821
• 153 Drobniewski F A, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis.  Lancet Infect Dis. 2003;  3 141-147
• 154 Barnes P F, Cave M D. Molecular epidemiology of tuberculosis.  N Engl J Med. 2003;  349 1149-1156
• 155 Mazurek G H, LoBue P A, Daley C L et al.. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection.  JAMA. 2001;  86 1740-1747
• 156 CDC . Guidelines for using the QuantiFERON^® - TB Test for diagnosing latent Mycobacterium tuberculosis infection.  MMWR Morb Mortal Wkly Rep. 2003;  52 15-18
• 157 Reichman L B. The U-shaped curve of concern.  Am Rev Respir Dis. 1991;  144 741-742
• 158 Stone R. Tuberculosis rebounds while funding lags.  Science. 1992;  255 1064
• 159 Toman K. Proceedings: modern methods of case finding.  Bull Int Union Tuberc. 1974;  49 S62-S63
• 160 Reported Tuberculosis Data, Calendar Year 1956 .U.S. Department of Health, Education, and Welfare, Public Health Service Publication No. 638. Washington, DC; United States Government Printing Office 1957
• 161 FDA .The Selection of Patients for X-Ray Examinations: Chest X-Ray Screening Examinations. HHS Publication No. 83-8204. Washington, DC; FDA 1983
• 162 Tizes R, Tizes C W. Decline in statewide mobile x-ray programs to detect tuberculosis.  Public Health Rep. 1970;  85 901-904
• 163 Special Tuberculosis Projects 1961-1965. Atlanta; U.S. Department of Health, Education, and Welfare 1966
• 164 Etkind S C. The role of the public health department in tuberculosis.  Med Clin North Am. 1993;  77 1303-1313
• 165 CDC .Reported Tuberculosis in the United States, 2002. Atlanta; U.S. Department of Health and Human Services, CDC 2003
• 166 CDC . Increase in African Immigrants and Refugees with Tuberculosis: Seattle-King County, Washington, 1998-2001.  MMWR Morb Mortal Wkly Rep. 2002;  51 882-883
• 167 Cookson S T, Jarvis W R. Prevention of nosocomial transmission of Mycobacterium tuberculosis .  Infect Dis Clin North Am. 1997;  11 385-409
• 168 Castro K G, Jaffe H W. Rationale and methods for the National Tuberculosis Genotyping and Surveillance Network.  Emerg Infect Dis. 2002;  8 1188-1191
• 169 CDC . What is a reportable case of tuberculosis?.  Public Health Rep. 1951;  66 1291-1294
• 170 Binkin N J, Zuber P L, Wells C D, Tipple M A, Castro K G. Overseas screening for tuberculosis in immigrants and refugees to the United States: current status.  Clin Infect Dis. 1996;  23 1226-1232
• 171 CDC . Guidelines for the control of pertussis outbreaks.  , Available at: http://www.cdc.gov/nip/publications/pertussis/guide.htm. Accessed February 25, 2004; 
• 172 Sumartojo E M, Geiter L J, Miller B, Hale B E. Can physicians treat tuberculosis? Report on a national survey of physician practices.  Am J Public Health. 1997;  87 2008-2011
• 173 Rao S N, Mookerjee A L, Obasanjo O O, Chaisson R E. Errors in treatment of tuberculosis in Baltimore.  Chest. 2000;  117 734-737
• 174 van Rie A, Warren R, Richardson M et al.. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.  N Engl J Med. 1999;  341 1174-1179
• 175 CDC .The National Plan to Eliminate Syphilis from the United States. Atlanta, Georgia; U.S. Department of Health and Human Services, CDC, National Center for HIV, STD, and TB Prevention 1999
• 176 Rothenberg R B, McElroy P D, Wilce M A, Muth S Q. Contact tracing: comparing the approaches for sexually transmitted diseases and tuberculosis.  Int J Tuberc Lung Dis. 2003;  7 S342-S348
• 177 Williams L A, Klausner J D, Whittington W L, Handsfield H H, Celum C, Holmes K K. Elimination and reintroduction of primary and secondary syphilis.  Am J Public Health. 1999;  89 1093-1097
• 178 Ginsberg A M. A proposed national strategy for tuberculosis vaccine development.  Clin Infect Dis. 2000;  30 S233-S242
• 179 Murray C JL, Salomon J A. Modeling the impact of global tuberculosis control strategies.  Proc Natl Acad Sci USA. 1998;  95 13881-13886
• 180 Manabe Y C, Bichai W R. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting.  Nat Med. 2000;  6 1327-1329

1 In their report, the Arden House members alternatively wrote of “eradication” and “elimination.” Apparently they did not observe current conventions, which define the first term as the abolition of all TB and the second as an indefinite suppression of TB to a predetermined minimal frequency.

2 Precursor of the American Lung Association.

3 See previous footnote.

4 The use of trade names is for information purposes only and does not constitute an endorsement by the United States Public Health Service or the Department of Health and Human Services.

5 “Active” and “inactive” radiographic cases; not distinguished in the reports.